Author: BusinessWire

 Guest speakers Include Deepak Bhatt, MD, MPH and John Fanikos, RPh, MBA

Presentations from PhaseBio Leadership Team
MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–$PHAS #TakeItToHeart–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biop…

VANCOUVER, Canada–(BUSINESS WIRE)–Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2020 and provided a summary of rece…

 Guest speakers Include Deepak Bhatt, MD, MPH and John Fanikos, RPh, MBA

Presentations from PhaseBio Leadership Team
MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–$PHAS #TakeItToHeart–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biop…

 Guest speakers Include Deepak Bhatt, MD, MPH and John Fanikos, RPh, MBA

Presentations from PhaseBio Leadership Team
MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–$PHAS #TakeItToHeart–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biop…

– Multiple key data read-outs expected for 2021, including the ARC-7 interim analysis in 2Q21

– Domvanalimab’s advancement into a registrational study coupled with recent IND clearance for AB308, Arcus’s FcR-enabled anti-TIGIT antibody, reinforces A…

NASHVILLE, Tenn.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company’s President and Chief Executive Officer, Mark Foley, will …

– LUPKYNISTM is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death –

– Cash, cash equivalents, and investments of $423 m…

– LUPKYNISTM is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death –

– Cash, cash equivalents, and investments of $423 m…

Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time
BRISBANE, Calif.–(BUSINESS WIRE)–Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported fourth quarter and full year 2020 financial results and recent bu…

DUBLIN–(BUSINESS WIRE)–The “Systemic Scleroderma Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Regions; Segment Forecast, 2021-2028” report has been added to ResearchAndMarkets.com’s offering.

The global systemic …